

Effect of deubiquitinase USP8 on hypoxia/reoxygenation-induced inflammation by deubiquitination of TAK1 in renal tubular epithelial cells

YUWEI ZHANG, YINGQUAN LUO, YINA WANG, HONG LIU, YU YANG and QIONG WANG

Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China

Received December 14, 2017; Accepted September 4, 2018

DOI: 10.3892/ijmm.2018.3881

Abstract. Intermittent hypoxia/reoxygenation (IHR), characterized by repeated episodes of hypoxia interspersed with periods of reoxygenation, has been found to induce pro-inflammatory cytokine production and is increasingly recognized as a major pathophysiological factor in various disease processes with distinct cell and molecular responses. The present study is the first, to the best of our knowledge, to investigate the effects of ubiquitin-specific peptidase 8 (USP8) on IHR-induced inflammation in renal tubular epithelial cells and examine the underlying mechanism. Following transfection of plasmids, HK-2 and TCMK-1 cells were incubated for eight cycles of IHR treatment including 3 h of hypoxic incubation followed by 3 h of normoxic culture. It was demonstrated that the expression of USP8 was decreased in IHR conditions but not in normoxic or continuous hypoxic conditions. In addition, IHR-induced inflammation was suppressed in USP8-overexpressing renal tubular epithelial cells, and the silencing of USP8 markedly aggravated inflammation. Furthermore, it was found that the overexpression of USP8 inhibited the IHR-induced activation of nuclear factor- κ B and it was demonstrated that USP8 interacted with transforming growth factor- β -activated kinase-1 (TAK1) and deubiquitinated the K63-linked ubiquitination of TAK1. Taken together, the results demonstrated the role of USP8 in IHR-induced inflammation and suggested USP8 as a potential and specific therapeutic target for IHR-related diseases.

Introduction

Intermittent hypoxia/reoxygenation (IHR) has been reported to contribute to the pathogenic process of obstructive sleep

apnea (OSA); it also appears to be involved in promoting resistance to radiotherapy and chemotherapy in solid tumors, and is encountered in a wide range of respiratory and cardiac disorders, including chronic obstructive pulmonary disease and congestive cardiac failure (1-5). During these disease processes, IHR is always associated with increased reactive oxygen species (ROS) production, oxidative stress, and inflammation (6,7). Emerging evidence indicates that chronic kidney disease is a prevalent complication of untreated OSA with symptoms of polyuria and proteinuria (8,9). However, the precise mechanisms between these two diseases remain to be fully elucidated.

In contrast to the adaptation effect in response to continuous hypoxia (CH) through hypoxia-inducible factor 1 (HIF-1) signaling, the body undergoes tissue damage and cellular inflammation, mainly caused by nuclear factor- κ B (NF- κ B) signaling, following IHR challenge (10). NF- κ B is considered the main pro-inflammatory family of transcription factors (11,12), NF- κ B is released consequently and translocates to the nucleus where it activates the expression of NF- κ B-related inflammatory genes (13). In this process, transforming growth factor- β -activated kinase-1 (TAK1) has been reported to be crucial through its kinase activity to phosphorylate and activate inhibitor of NF- κ B (I κ B) kinase (IKK) β , facilitating IKK β -mediated I κ B α degradation and downstream activation of NF- κ B (14). However, the role of TAK1 in the IHR-induced activation of NF- κ B has not been reported.

Deubiquitination is catalyzed by deubiquitinating (DUB) enzymes, which are proteases that cleave ubiquitin or ubiquitin-like proteins from target proteins (15). Ubiquitin-specific peptidase 8 (USP8; also known as Ubpy) is a cysteine protease and member of the ubiquitin-specific protease family of DUB enzymes capable of catalyzing the complete breakdown of K48- and K63-linked polyubiquitin into its component monomers (16,17). USP8 has an important physiological function in cell growth, and the deletion of USP8 causes embryonic death in mice (18,19). USP8 has been reported to negatively regulate the ubiquitination of epidermal growth factor receptor, neuregulin receptor degradation protein-1, and β -site amyloid precursor protein-cleaving enzyme to regulate the process of cell proliferation, neuroinflammation and neurological disorder (20-23). However, the effect of USP8 on IHR-induced inflammation and the underlying targets in the IHR-induced

Correspondence to: Dr Yu Yang, Department of Geriatrics, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, Hunan 410011, P.R. China
E-mail: yangyu_changsha@163.com

Key words: ubiquitin-specific peptidase 8, intermittent hypoxia/reoxygenation, inflammation, transforming growth factor- β -activated kinase-1

activation of NF- κ B remain to be fully elucidated. The present study demonstrated for the first time, to the best of our knowledge, that the expression of USP8 was decreased in IHR conditions but not in normoxic or CH conditions in renal tubular epithelial cells. Furthermore, the overexpression of USP8 significantly suppressed IHR-induced pro-inflammatory cytokine expression and inhibited the activation of NF- κ B. It was also observed that USP8 interacted with TAK1 and deubiquitinated the K63-linked ubiquitination of TAK1, leading to the inactivation of TAK1 and NF- κ B. In conclusion, the present study revealed an anti-inflammatory role of USP8 in IHR-induced inflammation and suggested USP8 as a potential target for the treatment of IHR-related diseases.

Materials and methods

Cell culture and hypoxia treatment. The HK-2 (human renal tubular epithelial cells) and TCMK-1 (murine renal tubular epithelial cells) cells were purchased from the American Type Culture Collection (Manassas, VA, USA). These cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) that was supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). The hypoxia treatment was performed as described previously (24). Briefly, for the normoxic cultures, the cells were cultured in a humidified incubator (37°C, 21% O₂, 74% N₂ and 5% CO₂) for 48 h. For the CH cultures, the cells were grown in a sealed hypoxic incubator for 48 h (37°C, 1% O₂, 94% N₂ and 5% CO₂). For the IHR cultures, the cells were subjected to a specified number of hypoxia (37°C, 1% O₂, 94% N₂ and 5% CO₂) and reoxygenation (37°C, 21% O₂, 74% N₂ and 5% CO₂) cycles; each hypoxia and reoxygenation cycle included 3 h of hypoxic incubation followed by 3 h of normoxic culture. When reoxygenated, the cell culture medium was replaced, and the culture dishes were placed into a normoxic chamber.

Plasmid and short hairpin (sh)RNA. The human USP8 and murine USP8 expression plasmids were purchased from Vigene Biosciences, Inc. (Jinan, China). Human USP8 and murine USP8 shRNA plasmids (cat. nos. 76975 and 76976) were purchased from Santa Cruz Biotechnology, Inc., (Dallas, TX, USA). For the transfection of plasmids into HK-2 and TCMK-1 cells, X-treme Gene 9 reagents were used according to the standard protocol (Roche Diagnostics, Basel, Switzerland). Following transfection, the cells were incubated at 37°C for 36 or 48 h to allow for maximal overexpression or knockdown of the target gene, and then exposed to eight cycles of IHR, followed by the examination of protein expression or inflammatory cytokine detection.

Dual-luciferase reporter gene assays. The experiment was performed as described previously (25). The NF- κ B promoter plasmid and phRL-TK plasmid were obtained from Dr Guo Litao from Affiliated Hospital of Chengde Medical University (Chengde, China). The reporter plasmid was transfected into HK-2 cells using the Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific, Inc.), and the phRL-TK plasmid was cotransfected as internal control. A total of 36 h later, the cells were exposed to IHR treatment

and the luciferase activities were measured on a SpectraMax M5 reader (Molecular Devices LLC, Sunnyvale, CA, USA) and normalized to *Renilla* luciferase activity using the Dual Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA).

RNA analysis. The cells were collected and TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA according to the manufacturer's protocol. The cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.) was used for using 1 μ g of total RNA from each sample according to the manufacturer's protocol. The temperature protocol was as follows: RNA and kit reagents were mixed and incubated for 2 min at 37°C in a water bath. Then the other components were added and incubated for 10 min at 25°C followed by 15 min at 50°C. The reaction was terminated by heating at 85°C for 5 min.

A LightCycler (ABI PRISM 7000; Applied Biosystems; Thermo Fisher Scientific, Inc.) and a SYBR RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) were used for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Reaction conditions for SYBR Green quantitative PCR were: Pre-denaturation at 95°C for 10 min; followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 20 sec, and extension at 72°C for 20 sec. GAPDH was used as the internal control, and the $2^{-\Delta\Delta C_q}$ method was used to evaluate the relative quantities of each amplified product in the samples (26). The primer sequences used in RT-qPCR analysis are presented in Table I.

Western blot analysis and immunoprecipitation (IP). The cells were lysed using RIPA buffer (Thermo Fisher Scientific, Inc.), and total protein in the supernatants was quantified using a BCA protein assay kit (Thermo Fisher Scientific, Inc.). IP and western blot analysis were performed as described previously (27). Equal amounts of protein (50 μ g protein per lane) were loaded on 10% SDS-PAGE for separating them and then transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% non-fat milk for 1 h, the membranes were probed with primary antibodies at 4°C overnight. The membranes were washed three times with TBS and 0.1% Tween 20 (TBST) the next day, and then incubated with HRP-conjugated anti-rabbit secondary antibodies (1:5,000; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. Following washing with TBST, the immunoreactive protein bands were visualized by using Western Blotting Luminol Reagent (cat. no. sc-2048; Santa Cruz Biotechnology, Inc.) and detected with Quantity One software version 4.6.2 (Bio-Rad Laboratories, Inc.). The antibodies targeting USP8 (1:1,000; cat. no. 8728), p65 (1:1,000; cat. no. 8242), phosphorylated (p)-p65 (1:1,000; cat. no. 3033), IKK β (1:1,000; cat. no. 8943), p-IKK β (1:1,000; cat. no. 2697), Flag (1:1,000; cat. no. 14793), Myc (1:1,000; cat. no. 2276), ubiquitin (linkage-specific K63; 1:500; cat. no. 5621) and β -actin (1:2,000; cat. no. 3700) were all purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).

Statistical analysis. All data are presented as the mean \pm standard deviation of three experiments. Statistical significance was determined with (two-tailed) Student's t-test, $P < 0.05$ was

Table I. List of primers used in the present study.

Number	Gene	Sequence (5'-3')
1	USP8 (<i>Homo sapiens</i>)	F AAA GAC AGG CAG GAG GAA GC R CCA ATG TGC CAC CAT CCT CT
2	USP8 (<i>Mus musculus</i>)	F AAC CAG CAC CAA GAA TAC CAA R CCG AAC TTC AGC CTC TTC GT
3	TNF- α (<i>Homo sapiens</i>)	F CTA AGA GGG AGA GAA GCA R AGA GGC TGA GGA ACA AGC
4	TNF- α (<i>Mus musculus</i>)	F GCC ACC ACG CTC TTC TGT CT R TGA GGG TCT GGG CCA TAG AAC
5	IL-6 (<i>Homo sapiens</i>)	F CCT TCG GTC CAG TTG CCT TCT R CCA GTG CCT CTT TGC TGC TTT
6	IL-6 (<i>Mus musculus</i>)	F ACA ACC ACG GCC TTC CC TAC R CAT TTC CAC GAT TTC CCA GA
7	IL-1 β (<i>Homo sapiens</i>)	F AGC TAC GAA TCT CCG ACC R TGG CCA CAA CAA CTG ACG
8	IL-1 β (<i>Mus musculus</i>)	F ACC TTC CAG GAT GAG GAC ATG R AAC GTC ACA CAC CAG CAG GTT
9	IL-8 (<i>Homo sapiens</i>)	F TTG CCA AGG AGT GCT AAA GAA R GCC CTC TTC AAA AAC TTC TCC
10	CXCL15 (<i>Mus musculus</i>)	F CAA GGC TGG TCC ATG CTC C R TGC TAT CAC TTC CTT TCT GTT GC
11	GAPDH (Universal primer)	F AAT GAC CCC TTC ATT GAC R TCC ACG ACG TAC TCA GCG

USP8, ubiquitin-specific peptidase 8; TNF- β , transforming growth factor- β ; IL, interleukin; CXCL15, chemokine (C-X-C motif) ligand 15; F, forward; R, reverse.

considered to indicate a statistically significant difference. All statistical analyses were conducted using SPSS software (SPSS program, version 13.0, SPSS, Inc., Chicago, IL, USA).

Results

Expression of USP8 is decreased in IHR-treated renal tubular epithelial cells. The present study first examined the expression of USP8 in normoxia, IHR or CH. As shown in Fig. 1A and B, the expression of USP8 was not affected by the CH conditions, however, it was significantly decreased in the IHR-treated HK-2 and TCMK-1 cells. The association between the expression of USP8 and IHR cycles was then examined. It was demonstrated that the mRNA and protein levels of USP8 were attenuated in a time-dependent manner (Fig. 1C and D), which indicated that, as the number of IHR cycles increased, the expression of USP8 was decreased.

Overexpression of USP8 alleviates IHR-induced inflammation. It has been reported that USP8 is essential in downregulating neuroinflammation (23); the present study investigate whether USP8 regulates the inflammation induced by IHR. First, USP8 was overexpressed in HK-2 and TCMK-1 cells, and the overexpression of USP8 was confirmed as shown in Fig. 2A and B. The mRNA and protein levels of pro-inflammatory cytokines were detected, and it was demonstrated that

these cytokines, including tumor necrosis factor (TNF)- α , interleukin (IL)-6, IL-8 and IL-1 β , were all downregulated in the USP8-overexpressing HK-2 cells following IHR challenge (Fig. 2C and D). Consistently, similar results were observed in the TCMK-1 cells (Fig. 2E and F).

Silencing of USP8 aggravates IHR-induced inflammation. An shRNA plasmid of USP8 was purchased to knock down the expression of USP8, and the effect of shRNAs was detected (Fig. 3A and B). As presented in Fig. 3C and D, the silencing of USP8 enhanced the IHR-induced production of TNF- α , IL-6, IL-8 and IL-1 β in the HK-2 cells. Consistent with these overexpression results, it was found that the expression of pro-inflammatory cytokines in TCMK-1 cells was also increased following USP8 shRNA treatment in IHR conditions.

USP8 inhibits IHR-induced activation of NF- κ B. It has been reported that IHR-induced inflammation occurs mainly through NF- κ B signalling (10). The present study investigated whether USP8 also regulates IHR-induced pro-inflammatory cytokine production through the NF- κ B pathway. As presented in Fig. 4A, a Dual-Luciferase Reporter Assay was used to examine the activation of NF- κ B signaling, and it was found that the overexpression of USP8 significantly suppressed the activation of NF- κ B in the IHR-treated HK-2 cells. Consistently, it was demonstrated that silencing of USP8 enhanced the IHR-induced




Figure 1. Expression of USP8 is decreased in IHR-treated renal tubular epithelial cells. (A) mRNA and protein levels of USP8 in HK-2 cells in normoxia, IHR or CH conditions. (B) mRNA and protein levels of USP8 in TCMK-1 cells in normoxia, IHR or CH conditions. (C) mRNA and protein levels of USP8 in HK-2 cells in different cycles of IHR. (D) mRNA and protein levels of USP8 in TCMK-1 cells in different numbers of cycles of IHR. Data are representative of three independent experiments (mean \pm standard deviation). ** $P < 0.01$; *** $P < 0.001$. USP8, ubiquitin-specific peptidase 8; N, normoxia; CH, continuous hypoxia; IHR, intermittent hypoxia/reoxygenation.

activation of NF- κ B (Fig. 4B). Subsequently, the phosphorylation of p65 and IKK β was examined, and it was demonstrated that the overexpression of USP8 inhibited the IHR-induced phosphorylation of p65 and IKK β (Fig. 4C and D).

USP8 interacts with TAK1 and deubiquitinates the K63-linked ubiquitination of TAK1. TAK1 has been demonstrated to be essential in regulating the activation of NF- κ B (14). The present study examined whether USP8 regulates TAK1 and thus affects the NF- κ B pathway. As presented in Fig. 5A, it was demonstrated that, following the overexpression of USP8, the

TAK1-induced activation of NF- κ B was suppressed, whereas IKK β -induced NF- κ B activation was not affected. IP experiments were performed to examine the interaction between TAK1 and USP8, and it was found that USP8 interacted with TAK1 (Fig. 5B). On examining whether the expression of TAK1 was regulated by USP8, however, it was observed that the expression of TAK1 was not affected by the overexpression of USP8 (Fig. 5C). USP8 is reported to be a deubiquitinating enzyme, and it has been reported to deubiquitinate the K63-linked ubiquitination of diverse targets (16,17), therefore, the present study examined the K63-linked ubiquitination




Figure 2. Overexpression of USP8 alleviates IHR-induced inflammation. (A) mRNA and protein levels of USP8 in USP8-overexpressing HK-2 cells. (B) mRNA and protein levels of USP8 in USP8-overexpressing TCMK-1 cells. (C) mRNA and (D) protein levels of TNF- α , IL-6, IL-8 and IL-1 β in USP8-overexpressing HK-2 cells in IHR conditions. (E) mRNA and (F) protein levels of TNF- α , IL-6, CXCL15 and IL-1 β in USP8-overexpressing TCMK-1 cells in IHR conditions. Data are representative of three independent experiments (mean \pm standard deviation). * P <0.05; ** P <0.01; *** P <0.001. USP8, ubiquitin-specific peptidase 8; IHR, intermittent hypoxia/reoxygenation; EV, empty vector; TNF- α , tumor necrosis factor- α ; IL, interleukin; CXCL15, chemokine (C-X-C motif) ligand 15.




Figure 3. Silencing of USP8 aggravates IHR-induced inflammation. (A) mRNA and protein levels of USP8 in USP8-silenced HK-2 cells. (B) mRNA and protein levels of USP8 in USP8-silenced TCMK-1 cells. (C) mRNA and (D) protein levels of TNF- α , IL-6, IL-8 and IL-1 β in USP8-silenced HK-2 cells in IHR conditions. (E) mRNA and (F) protein levels of TNF- α , IL-6, CXCL15 and IL-1 β in USP8-silenced TCMK-1 cells in IHR conditions. Data are representative of three independent experiments (mean \pm standard deviation). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. USP8, ubiquitin-specific peptidase 8; IHR, intermittent hypoxia/reoxygenation; TNF- α , tumor necrosis factor- α ; IL, interleukin; CXCL15, chemokine (C-X-C motif) ligand 15; shRNA, short hairpin RNA; NC, negative control.




Figure 4. USP8 inhibits IHR-induced NF- κ B activation. (A) HK-2 cells were transfected with control or USP8 expression plasmid, followed by transfection with the NF- κ B reporter plasmid together with the phRL-TK plasmid (internal control); 36 h later the cells were treated with eight cycles of IHR, the activation of NF- κ B promoter was measured using a Dual-Luciferase reporter gene assay. (B) HK-2 cells were transfected with the shRNA-NC or shRNA-USP8 plasmid, followed by transfection with the NF- κ B reporter plasmid together with the phRL-TK plasmid (internal control); 36 h later the cells were treated with eight cycles of IHR, the activation of NF- κ B promoter was measured using a Dual-Luciferase reporter gene assay. (C) Phosphorylation of p65 and IKK β were examined by a western blot assay in USP8-overexpressing HK-2 cells treated with eight cycles of IHR and (D) protein levels protein levels of p-p65 and p-IKK β were quantified. Data are representative of three independent experiments (mean \pm standard deviation). * P <0.05; ** P <0.01; *** P <0.001. USP8, ubiquitin-specific peptidase 8; shRNA, short hairpin RNA; NC, negative control; N, normoxia; IHR, intermittent hypoxia/reoxygenation; NF- κ B, nuclear factor- κ B; IKK β , inhibitor of NF- κ B kinase β ; p-, phosphorylated.




Figure 5. USP8 interacts with TAK1 and deubiquitinates the K63-linked ubiquitination of TAK1. (A) HK-2 cells were treated with control or USP8 expression plasmid, followed by transfection with the NF- κ B reporter plasmid, pRL-TK plasmid, together with the control, TAK1 or IKK β expression plasmid; 36 h later, the cells were treated with eight cycles of IHR and activation of the NF- κ B promoter was measured using a Dual-Luciferase reporter gene assay. (B) HK-2 cells were transfected with Myc-TAK1 and Flag-USP8 expression plasmids, and the interaction between TAK1 and USP8 was examined by immunoprecipitation and western blot experiments. (C) HK-2 cells were transfected with Myc-TAK1, and co-transfected with increasing quantities of Flag-USP8 plasmid; the expression of TAK1 was examined by western blot analysis. (D) Western blot analysis of the K63-linked ubiquitination level of TAK1 in control- or USP8 expression plasmid-treated HK-2 cells in normoxia or IHR conditions. Data are representative of three independent experiments (mean \pm standard deviation). * P <0.05; *** P <0.001. IHR, intermittent hypoxia/reoxygenation; N, normoxia; NF- κ B, nuclear factor- κ B; IKK β , inhibitor of NF- κ B kinase β ; TAK1, transforming growth factor- β -activated kinase-1; WCL, whole cell lysis.

level of TAK1. As shown in Fig. 5D, following IHR treatment, the overexpression of USP8 downregulated the K63-linked ubiquitination of TAK1, indicating that USP8 suppressed the activation of TAK1 through regulating TAK1 K63-linked ubiquitination.

Discussion

To the best of our knowledge, the present study is the first to demonstrate the essential role of USP8 in IHR-induced inflammation in renal tubular epithelial cells. It is also the first report to reveal that TAK1 is one of the targets of USP8 and provide evidence to illustrate that USP8 negatively regulates

the activity of TAK1 through deubiquitinating the K63-linked ubiquitination of TAK1.

During the progression of acute kidney injury, renal tubular epithelial cells undergo ischemia and hypoxia, which include a series of events that cause pathological damage (28,29). Patients with severe OSA also exhibit a high prevalence of chronic kidney disease and it has been found to accelerate the loss of kidney function (30). Therefore, it is of significance to examine the underlying pathogenesis of the disease and identify other appropriate drug targets. In the present study, it was found that, in cultured human and murine renal tubular epithelial cells, the expression of USP8 was significantly decreased in IHR conditions, however, the expression of USP8 was not

affected in CH conditions. It was hypothesized that this may relate to the oxidative stress and production of ROS induced by IHR, and future investigations aim to investigate this to confirm this hypothesis.

It has been reported that NF- κ B-dependent inflammatory gene expression is induced by IHR (10). Consistent with previous studies, the present study found in renal tubular epithelial cells that the activation of NF- κ B and pro-inflammatory cytokine production was increased in IHR conditions. It was also observed that USP8 markedly suppressed the IHR-induced activation of NF- κ B and cytokine production, indicating that USP8 has an anti-inflammatory effect on IHR-induced inflammation. For the first time, to the best of our knowledge, the present study revealed that TAK1 is a target of USP8. TAK1 directly interacted with USP8, and the overexpression of USP8 significantly suppressed the TAK1-induced activation of NF- κ B. These findings also indicated that TAK1 is the key regulator of IHR-induced pro-inflammatory cytokine production, which improves current understanding of TAK1-related diseases.

Ubiquitin has seven lysines (K6, K11, K27, K29, K33, K48 and K63), all of which can be conjugated to another ubiquitin to form a polyubiquitin chain through different lysine linkages to serve distinct functions in the cells (31). The K63-linked polyubiquitination of TAK1 has been reported to be crucial in the activation of TAK1 and NF- κ B (32,33). In the present study, it was found that E3 ligase USP8 directly interacted with TAK1, but the overexpression of USP8 did not affect the expression of TAK1, indicating that the K48-linked polyubiquitination of TAK1 was not regulated by USP8. Finally, it was observed that USP8 cleaved K63-linked polyubiquitin chains from TAK1 to inhibit TAK1 kinase activity, leading to the attenuated activation of NF- κ B and IHR-induced inflammation. This provides novel ideas for drug development for IHR-related diseases, including OSA.

In conclusion, the present study found that the expression of USP8 was decreased in renal tubular epithelial cells in IHR conditions, and USP8 suppressed the IHR-induced activation of NF- κ B and pro-inflammatory cytokine production, mainly through deubiquitinating the K63-linked ubiquitination of TAK1. The results demonstrated the role of USP8 in IHR-induced inflammation and suggested USP8 as a potential and specific therapeutic target for IHR-related diseases.

Acknowledgements

The authors would like to thank Dr. Guo Litao from the Affiliated Hospital of Chengde Medical University for providing plasmids.

Funding

The present study was supported by grants from Natural Science Foundation of China (grant nos. 30700890 and 81100059).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YWZ and YQL performed the experiments and drafted the manuscript. YW and HL assisted with the cell culture and western blot. YY and QW conceived and designed the study, analyzed and interpreted the data, and critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors confirm that they have no competing interests.

References

1. Passali D, Corallo G, Yaremchuk S, Longini M, Proietti F, Passali GC and Bellussi L: Oxidative stress in patients with obstructive sleep apnoea syndrome. *Acta Otorhinolaryngol Ital* 35: 420-425, 2015.
2. Toffoli S and Michiels C: Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. *FEBS J* 275: 2991-3002, 2008.
3. Prabhakar NR: Oxygen sensing during intermittent hypoxia: Cellular and molecular mechanisms. *J Appl Physiol* 90: 1986-1994, 2001.
4. Agani F and Jiang BH: Oxygen-independent regulation of HIF-1: Novel involvement of PI3K/AKT/mTOR pathway in cancer. *Curr Cancer Drug Targets* 13: 245-251, 2013.
5. Wang Z, Wu S, Liao J, Zhong L, Xing T, Fan J and Peng Z: Interleukin-6 and rs1800796 locus single nucleotide polymorphisms in response to hypoxia/reoxygenation in hepatocytes. *Int J Mol Med* 38: 192-200, 2016.
6. Dyugovskaya L, Polyakov A, Lavie P and Lavie L: Delayed neutrophil apoptosis in patients with sleep apnea. *Am J Respir Crit Care Med* 177: 544-554, 2008.
7. Lavie L: Oxidative stress in obstructive sleep apnea and intermittent hypoxia-revisited-the bad ugly and good: Implications to the heart and brain. *Sleep Med Rev* 20: 27-45, 2015.
8. Nicholl DD, Ahmed SB, Loewen AH, Hemmelgarn BR, Sola DY, Beecroft JM, Turin TC and Hanly PJ: Clinical presentation of obstructive sleep apnea in patients with chronic kidney disease. *J Clin Sleep Med* 8: 381-387, 2012.
9. Kimmel PL, Miller G and Mendelson WB: Sleep apnea syndrome in chronic renal disease. *Am J Med* 86: 308-314, 1989.
10. Ryan S, McNicholas WT and Taylor CT: A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. *Biochem Biophys Res Commun* 355: 728-733, 2007.
11. Li D, Wang C, Li N and Zhang L: Propofol selectively inhibits nuclear factor-kappaB activity by suppressing p38 mitogen-activated protein kinase signaling in human EA.hy926 endothelial cells during intermittent hypoxia/reoxygenation. *Mol Med Rep* 9: 1460-1466, 2014.
12. Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol* 1: a001651, 2009.
13. Tian Y, Zhang Y, Zhong B, Wang YY, Diao FC, Wang RP, Zhang M, Chen DY, Zhai ZH and Shu HB: RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation. *J Biol Chem* 282: 16776-16782, 2007.
14. Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, Murphy TF, Lim DJ and Li JD: Activation of NF-kappa B by nontypeable *Hemophilus influenzae* is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. *Proc Natl Acad Sci USA* 98: 8774-8779, 2001.

15. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and functional inventory of deubiquitinating enzymes. *Cell* 123: 773-786, 2005.
16. MacDonald E, Urbe S and Clague MJ: USP8 controls the trafficking and sorting of lysosomal enzymes. *Traffic* 15: 879-888, 2014.
17. Jeong M, Lee EW, Seong D, Seo J, Kim JH, Grootjans S, Kim SY, Vandenabeele P and Song J: USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability. *Oncogene* 36: 458-470, 2017.
18. Naviglio S, Matteucci C, Matoskova B, Nagase T, Nomura N, Di Fiore PP and Draetta GF: UBPY: A growth-regulated human ubiquitin isopeptidase. *EMBO J* 17: 3241-3250, 1998.
19. Niendorf S, Oksche A, Kisser A, Löhler J, Prinz M, Schorle H, Feller S, Lewitzky M, Horak I and Knobloch KP: Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. *Mol Cell Biol* 27: 5029-5039, 2007.
20. Alwan HA and van Leeuwen JE: UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation. *J Biol Chem* 282: 1658-1669, 2007.
21. Wu X, Yen L, Irwin L, Sweeney C and Carraway KL, III: Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. *Mol Cell Biol* 24: 7748-7757, 2004.
22. Yeates EF and Tesco G: The endosome-associated deubiquitinating enzyme USP8 regulates bACE1 enzyme ubiquitination and degradation. *J Biol Chem* 291: 15753-15766, 2016.
23. Zhu L, Bi W, Lu D, Zhang C, Shu X, Wang H, Qi R, Shi Q and Lu D: Regulation of ubiquitin-specific processing protease 8 suppresses neuroinflammation. *Mol Cell Neurosci* 64: 74-83, 2015.
24. Litao L, Wenlan L, Lili W, Ting Z, Jianhua Z, and Ni X: Hypoxia-inducible factor 1 mediates intermittent hypoxia-induced migration of human breast cancer MDAMB231 cells. *Oncol Lett* 14: 7715-7722, 2017.
25. Guo L, Dong W, Fu X, Lin J, Dong Z, Tan X and Zhang T: Tripartite Motif 8 (TRIM8) positively regulates pro-inflammatory responses in *Pseudomonas aeruginosa*-induced keratitis through promoting K63-linked polyubiquitination of TAK1 protein. *Inflammation* 40: 454-463, 2017.
26. Kenneth J and Livak TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Method* 25: 402-408, 2001.
27. Lin Y and Luo Z: NLRP6 facilitates the interaction between TAB2/3 and TRIM38 in rheumatoid arthritis fibroblast-like synoviocytes. *FEBS Lett* 591: 1141-1149, 2017.
28. Bonventre JV and Yang L: Cellular pathophysiology of ischemic acute kidney injury. *J Clin Invest* 121: 4210-4221, 2011.
29. Cantaluppi V, Quercia AD, Dellepiane S, Figliolini F, Medica D and De Lena M: New mechanisms and recent insights in the pathogenesis of acute kidney injury (AKI). *G Ital Nefrol* 29: 535-547, 2012 (In Italian).
30. Yayan J, Rasche K and Vlachou A: Obstructive sleep apnea and chronic kidney disease. *Adv Exp Med Biol* 1022: 11-18, 2017.
31. Adhikari A and Chen ZJ: Diversity of polyubiquitin chains. *Dev Cell* 16: 485-486, 2009.
32. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH and Landström M: The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. *Nat Cell Biol* 10: 1199-1207, 2008.
33. Fan YH, Yu Y, Mao RF, Tan XJ, Xu GF, Zhang H, Lu XB, Fu SB and Yang J: USP4 targets TAK1 to downregulate TNFalpha-induced NF-kappaB activation. *Cell Death Differ* 18: 1547-1560, 2011.